



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. PLATA-SALAMAN et al.
Group Art Unit	1614
Examiner Name	William Jarvis
Attorney Docket Number	ORT-1583

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
PS	✓	STEIN, M.B., <i>Neurobiological Perspectives on Social Phobia: From Affiliation to Zoology</i> , Biol. Psychiatry, 1998, 44 (12), 1277-1285.	
PS	✓	NEWBURN, G., <i>Psychiatric Disorders Associated with Traumatic Brain Injury, Optimal Treatment</i> , CNS Drugs, 1998, 9 (6), 441-456.	
PS	✓	LIDBERG, L., et al., <i>Suicide Attempts and Impulse Control Disorder are Related to Low Cerebrospinal Fluid 5-HIAA in Mentally Disordered Violent Offenders</i> , Acta Psychiatr. Scand., 2000, 101 (5), 395-402.	
PS	✓	VAN AMERINGEN, M., et al., <i>Drugs in Development for Social Anxiety Disorder: More to Social Anxiety Than Meets the SSRI</i> , Expert Opin. Invest. Drugs, 2000, 9 (10), 2215-2231.	
PS	✓	ZHUANG, S., et al., <i>Altered Emotional States in Knockout Mice Lacking 5-HT1A or 5-HT1B Receptors</i> , Neuropsychopharmacology, 1999, 21 (2S), 52S-60S.	
PS	✓	IWATA, Y., et al., <i>Carbamazepine Augmentation of Clomipramine in the Treatment of Refractory Obsessive-Compulsive Disorder</i> [letter], J. Clinical Psychiatry, 2000, 61 (7), 528-529.	
PS	✓	HOLLANDER, E., <i>Managing Aggressive Behavior in Patients with Obsessive-Compulsive Disorder and Borderline Personality Disorder</i> , J. Clinical Psychiatry, 1999, 60 (Suppl), 1538-1544.	
PS	✓	CORA-LOCATELLI, G., et al., <i>Gabapentin Augmentation for Fluoxetine-Treated Patients with Obsessive-Compulsive Disorder</i> [letter], J. Clinical Psychiatry, 1998, 59 (9), 480-481.	
PS	✓	KOOPOWITZ, L.E., et al., <i>Response of Obsessive Compulsive Disorder to Carbamazepine in Two Patients with Comorbid Epilepsy</i> , Annals of Clinical Psychiatry, 1997, 9 (3), 171-173.	
PS	✓	JEFFERSON, J.W., <i>Benzodiazepines and Anticonvulsants for Social Phobia (Social Anxiety Disorder)</i> , J. Clin. Psychiatry, 2001, 62 (Suppl. 1), 50-53.	
PS	✓	CONNOR, K.M., et al., <i>Social Phobia: Issues in Assessment and Management</i> , Epilepsia, 1999, 40 (Suppl 6), S60-65.	
PS	✓	DISCUSSION S60-65.	
PS	✓	BRODSKY, L., et al., <i>Post Traumatic Stress Disorder: An Eclectic Approach</i> , International Journal of Psychosomatics, 1990, 37 (1-4), 89-95.	
PS	✓	ADAMEC, R., et al., <i>Effects of Baseline Anxiety on Response to Kindling of the Right Medial Amygdala</i> , Physiol. Behav., 2000, 70 (1/2), 67-80.	
PS	✓	FRIEDMAN, M.J., <i>What Might the Psychobiology of Posttraumatic Stress Disorder Teach Us About Future Approaches to Pharmacotherapy?</i> , J. clin. Psychiatry, 2000, 61 (Suppl. 7), 44-51.	
PS	✓	STAM, R., et al., <i>Long-lasting Stress Sensitisation</i> , Eur. J. Pharmacol., 2000, 405 (1-3), 217-224.	
PS	✓	SOUTHWICK, S.M., et al., <i>Role of Norepinephrine in the Pathophysiology and Treatment of Posttraumatic Stress Disorder</i> , Biol. Psychiatry, 1999, 46 (9), 1192-1204.	
PS	✓	HERTZBERG, M.A., et al., <i>A Preliminary Study of Lamotrigine for the Treatment of Posttraumatic Stress Disorder</i> , Biol. Psychiatry, 1999, 45, 1226-1229.	
PS	✓	DAVIDSON, J., <i>Biological Therapies for Posttraumatic Stress Disorder: An Overview</i> , J. Clinical Psychiatry, 1997, 58 (Suppl), 29-32.	
PS	✓	FRIEDMAN, M.J., <i>Drug Treatment for PTSD, Answers and Questions</i> , Annals of the New York Academy of Sciences, 1997 (JUN 21), 821, 359-371.	
PS	✓	FORD, N., <i>The Use of Anticonvulsants in Posttraumatic Stress Disorder: Case Study and Overview</i> , J. Traumatic Stress, 1996, 9 (4), 857-863.	
PS	✓	SUTHERLAND, S.M., et al., <i>Pharmacotherapy for Post-Traumatic Stress Disorder</i> , Psychiatric Clinics of North America, 1994, 17 (2), 409-423.	
PS	✓	KECK, P.E., et al., <i>Valproate and Carbamazepine in the Treatment of Panic and Posttraumatic Stress Disorders, Withdrawal States, and Behavioral Dyscontrol Syndromes</i> , J. OF CLINICAL Psychopharmacology, 1992, 12 (1 Suppl), 36S-41S.	
PS	✓	BERIGAN, T., et al., <i>Valproate as an Alternative in Post-Traumatic Stress Disorder: A Case Report</i> , Military Medicine, 1995, 160 (6) 318.	
PS	✓	BERLANT, J., <i>Topiramate in Chronic Civilian Posttraumatic Stress Disorder – An Open Label Study of a Novel Treatment</i> , International Society for Traumatic Stress Studies, Melbourne, Australia, 2000.	
PS	✓	BRANNON, N., et al., <i>Gabapentin Treatment for Posttraumatic Stress Disorder</i> , Canadian J. Psychiatry, 2000, 45 (1) 84.	
PS	✓	CLARK, R.D., et al., <i>Divalproex in Posttraumatic Stress Disorder: An Open-Label Clinical Trial</i> , J. Trauma. Stress, 1999, 12 (2) 395-401.	
PS	✓	FESLER, F.A., <i>Valproate in Combat-Related Posttraumatic Stress Disorder</i> , J. Clin. Psychiatry, 1991, 52 (9) 361-364.	

Examiner Signature	Date Considered
--------------------	-----------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002, OMB 0651-0031

Approved for use through 10/31/2002. GMD 00010001
Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. PLATA-SALAMAN et al.
Group Art Unit	1614
Examiner Name	William Jarvis
Attorney Docket Number	ORT-1583

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

**Examiner
Signature**

Phyllis Spinack

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. PLATA-SALAMAN et al.
Group Art Unit	1614
Examiner Name	William Jarvis
Attorney Docket Number	ORT-1583

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENT

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



JUN 11 2003

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. Plata-Salaman
Group Art Unit	1614
Examiner Name	SPIVACK
Attorney Docket Number	ORT-1583

U.S. PATENT DOCUMENTS

RECEIVED
JUL 25 2003
ECHO CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner
Signature

Phillip Spivack

Date Considered

9/10/03

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if applicable. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

JUN 11 2003

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Attachment 3
Assessment for use through 10/31/2012 OMB 0651-0031

Approved for Use through 10/31/2002. GPO 003-0001
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. Plata-Salaman
Group Art Unit	1614
Examiner Name	W. Jarvis
Attorney Docket Number	ORT-1583

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

**Examiner
Signature**

Phyllis Spivack

Date Considered

9/10/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in subject considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with your comments.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

11. **Time:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the complexity of the information being reported. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

JUN 11 2003

TECH CENTER 1600/2900

JUN 09 2003

SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/081,713
Filing Date	February 21, 2002
First Named Inventor	C. Plata-Salaman
Group Art Unit	1614
Examiner Name	W. Jarvis
Attorney Docket Number	ORT-1583

U.S. PATENT DOCUMENTS

JUL 25 2003

RECEIVED

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature _____ Date Considered _____